Related Articles for PubMed (Select 18799008)

Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules.

Schrader S, Chuck SK, Rahn LW, Parekh P, Emrich KG.

AIDS Res Ther. 2008 Sep 17;5:21.

PMID: 18799008 [PubMed - in process]

Related Articles Free article in PMC

A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks.

Molina JM, Podsadecki TJ, Johnson MA, Wilkin A, Domingo P, Myers R, Hairrell JM, Rode RA, King MS, Hanna GJ.

AIDS Res Hum Retroviruses. 2007 Dec;23(12):1505-14.

PMID: 18160008 [PubMed - indexed for MEDLINE]

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, Fourie J, De Meyer S, De Pauw M, Lefebvre E, Vangeneugden T, Spinosa-Guzman S.

AIDS. 2008 Jul 31;22(12):1389-97.

PMID: 18614861 [PubMed - indexed for MEDLINE]

The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect.

Klein CE, Chiu YL, Awni W, Zhu T, Heuser RS, Doan T, Breitenbach J, Morris JB, Brun SC, Hanna GJ.

J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):401-10.

PMID: 17224848 [PubMed - indexed for MEDLINE]

Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations.

Johnson M, Nieto-Cisneros L, Horban A, Arasteh K, Gonzalez-Garcia J, Artigas JG, Clotet B, Danise A, Landman R, Proll S, Snowden W, Foreman R, Smith P.

HIV Med. 2005 Mar;6(2):107-13.

PMID: 15807716 [PubMed - indexed for MEDLINE]

Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy.

Maitland D, Jackson A, Osorio J, Mandalia S, Gazzard BG, Moyle GJ; Epivir-Ziagen (EZ) Switch Study Team.

HIV Med. 2008 Oct;9(8):667-72. Epub 2008 Jul 8.

PMID: 18631255 [PubMed - in process]

[Longitudinal study on adherence, treatment satisfaction, and effectiveness of once-daily versus twice-daily antiretroviral therapy in a Spanish cohort of HIV-infected patients (CUVA study)]

Viciana P, Rubio R, Ribera E, Knobel H, Iribarren JA, Arribas JR, Pérez-Molina JA; Investigadores del Estudio CUVA.

Enferm Infecc Microbiol Clin. 2008 Mar;26(3):127-34. Spanish.

PMID: 18358210 [PubMed - indexed for MEDLINE]

Tolerability of enteric-coated didanosine capsules compared with didanosine tablets in adults with HIV infection.

Kunches LM, Reinhalter NE, Marquis A, Coakley E, Cohen C, Morris AB, Mazzullo JM.

J Acquir Immune Defic Syndr. 2001 Oct 1;28(2):150-3.

PMID: 11588508 [PubMed - indexed for MEDLINE]

The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation.

Leist TP, Vermersch P.

Curr Med Res Opin. 2007 Nov;23(11):2667-76. Review.

PMID: 17880754 [PubMed - indexed for MEDLINE]

10:

Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.

Barragan P, Podzamczer D.

Expert Opin Pharmacother. 2008 Sep;9(13):2363-75. Review.

PMID: 18710360 [PubMed - indexed for MEDLINE]

11:

Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.

Spire B, Marcellin F, Cohen-Codar I, Flandre P, Boue F, Dellamonica P, Raffi F, Norton M, Van Philippe N, Delfraissy JF.

Antivir Ther. 2008;13(4):591-9.

PMID: 18672538 [PubMed - indexed for MEDLINE]

12:

The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.

Gupta SK, Rosenkranz SL, Cramer YS, Koletar SL, Szczech LA, Amorosa V, Hall SD.

AIDS. 2008 Oct 1;22(15):1919-27.

PMID: 18784455 [PubMed - indexed for MEDLINE]

13:

An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey.

Granger AL, Fehnel SE, Hogue SL, Bennett L, Edin HM.

J Affect Disord. 2006 Feb;90(2-3):217-21. Epub 2005 Dec 15.

PMID: 16360216 [PubMed - indexed for MEDLINE]

14:

Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients.

Wright D, Rodriguez A, Godofsky E, Walmsley S, Labriola-Tompkins E, Donatacci L, Shikhman A, Tucker E, Chiu YY, Chung J, Rowell L, Demasi R, Graham N, Salgo M.

HIV Clin Trials. 2008 Mar-Apr;9(2):73-82.

PMID: 18474492 [PubMed - indexed for MEDLINE]

15:

Saquinavir-soft gel: establishing saquinavir in HAART regimens.

Moyle GJ.

Expert Opin Investig Drugs. 1998 Aug;7(8):1313-22.

PMID: 15992033 [PubMed]

16:

Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression.

Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW.

HIV Clin Trials. 2008 May-Jun;9(3):164-76.

PMID: 18547903 [PubMed - indexed for MEDLINE]

17:

Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.

Carr A, Ritzhaupt A, Zhang W, Zajdenverg R, Workman C, Gatell JM, Cahn P, Chaves R.

AIDS. 2008 Nov 12;22(17):2313-21.

PMID: 18981770 [PubMed - in process]

18:

[Preferences, satisfaction and compliance with antiretroviral treatment: ARPAS study (II)]

Ventura Cerdá JM, Casado Gómez MA, Escobar Rodríguez I, Ibarra Barrueta O, Ortega Valín L, Morales González JM, Cotarelo Suárez M; estudio ARPAS (II).

Farm Hosp. 2007 Nov-Dec;31(6):340-52. Spanish.

PMID: 18348665 [PubMed - indexed for MEDLINE]

19:

Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.

Keiser PH, Nassar N.

Int J STD AIDS. 2008 Aug;19(8):561-2.

PMID: 18663047 [PubMed - indexed for MEDLINE]

20:

Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.

Elion R, Cohen C, Ward D, Ruane P, Ortiz R, Reddy YS, Ebrahimi R, McColl D, Kearney B, Fisher A, Flaherty J; BATON Study Group.

HIV Clin Trials. 2008 Jul-Aug;9(4):213-24.

PMID: 18753116 [PubMed - indexed for MEDLINE]

Recent Activity